CoChat

Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Autism

Hviid, Anders, Melbye, Mads, Pasternak, Björn · 2013 · New England Journal of Medicine

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Studies have raised concern about an association between the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and an increased risk of autism spectrum disorders in the offspring. METHODS: We conducted a cohort study of all singleton live births in Denmark from 1996 through 2005 (626,875 births), with follow-up through 2009. Using Danish population registries, we linked information on maternal use of SSRIs before and during pregnancy, autism spectrum disorders diagnosed in the offspring, and a range of potential confounders. We used a survival analysis of the time to diagnosis in the offspring with Poisson regression to estimate rate ratios of autism spectrum disorders according to maternal use of SSRIs. RESULTS: During 5,057,282 person-years of follow-up, we identified 3892 cases of autism spectrum disorder (incidence rate, 77.0 per 100,000 person-years). A total of 52 cases during 42,400 person-years of follow-up involved offspring of women who were exposed to SSRIs during their pregnancy (incidence rate, 122.6 per 100,000 person-years). As compared with no use of SSRIs both before and during pregnancy, use during pregnancy was not associated with a significantly increased risk of autism spectrum disorders (fully adjusted rate ratio, 1.20; 95% confidence interval [CI], 0.90 to 1.61). Among women who received SSRIs before pregnancy but not during pregnancy, the corresponding fully adjusted rate ratio was 1.46 (95% CI, 1.17 to 1.81). CONCLUSIONS: We did not detect a significant association between maternal use of SSRIs during pregnancy and autism spectrum disorder in the offspring. On the basis of the upper boundary of the confidence interval, our study could not rule out a relative risk up to 1.61, and therefore the association warrants further study. (Funded by the Danish Health and Medicines Authority.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1301449

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Research works printed but not linked: 4

  1. Knudsen LB, 1998, Dan Med Bull, 45, 320
  2. Jorgensen FS, 2003, Ugeskr Laeger, 165, 4404
  3. Poisson and logistic regression. In: Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993;227-36.
  4. 2012, MMWR Surveill Summ, 61, 1

Cited by

See all 207

Metadata

Authors
Hviid, A., Melbye, M., & Pasternak, B.
Affiliations
Statens Serum Institut (DK)
Venue
New England Journal of Medicine
Published
2013-12-19
Volume
369
Issue
25
Pages
2406-2415
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2061360351
Cited by
195
References
24
Citations by year
2026: 5 · 2025: 9 · 2024: 4 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 16 · 2019: 21 · 2018: 18 · 2017: 30 · 2016: 30 · 2015: 24 · 2014: 15 · 2013: 1
FWCI
23.80
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
Keywords
selective serotonin reuptake inhibitors, autism spectrum disorder, maternal antidepressant use, pregnancy, prenatal drug exposure, antidepressant safety in pregnancy
MeSH terms
Adult, Child Development Disorders, Pervasive, Denmark, Female, Follow-Up Studies, Humans, Pregnancy, Prenatal Exposure Delayed Effects, Registries, Risk, Incidence, Confidence Intervals, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.